Author:
Parveen Sheikdawood,Sathiyapriya T.,Tharani D.,Mohammed Riyaz S. U.,Dinesh Rakshi Anuja,Shanmugam Jayashree,Rajakumar K.,Zherebtsov Dmitry,Dhayalan Manikandan,Stalin Antony
Publisher
Springer Nature Singapore
Reference39 articles.
1. Amiri-Kordestani, L., Blumenthal, G.M., Xu, Q.C., Zhang, L., Tang, S.W., Ha, L., Weinberg, W.C., Chi, B., Candau-Chacon, R., Hughes, P., Russell, A.M.: FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast CancerFDA Approval Summary for T-DM1 for HER2+ MBC. Clin. Cancer Res. 20(17), 4436–4441 (2014)
2. Beck, A., Wurch, T., Bailly, C., Corvaia, N.: Strategies and challenges for the next generation of therapeutic antibodies. Nat. Rev. Immunol. 10(5), 345–352 (2010)
3. Birrer, M.J., Moore, K.N., Betella, I., Bates, R.C.: Antibody-drug conjugate-based therapeutics: state of the science. JNCI: J. Natl. Cancer Inst. 111(6), 538–49 (2019)
4. Bross, P.F., Beitz, J., Chen, G., Chen, X.H., Duffy, E., Kieffer, L., Roy, S., Sridhara, R., Rahman, A., Williams, G., Pazdur, R.: Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin. Cancer Res. 7(6), 1490–1496 (2001)
5. Canepa, E., Salassi, S., Simonelli, F., Ferrando, R., Rolandi, R., Lambruschini, C., Canepa, F., Dante, S., Relini, A., Rossi, G.: Non-disruptive uptake of anionic and cationic gold nanoparticles in neutral zwitterionic membranes. Sci. Rep. 11(1), 1256 (2021)